[Therapeutic Outcomes of 28 ALL Patients with MLL Gene Rearrangement]

To analyze the therapeutic outcomes of acute lymphoblastic leukemia(ALL) patients with MLL gene rearrangement.Clinical outcomes of 28 ALL patients aged less than 12 years old with MLL gene rearrangement treated with Chinese Childhood Leukemia Group ALL 2008 (CCLG -ALL 2008) protocol from January 2008 to April 2015 were retrospectively analyzed.Among 28 patients, 14 were boys and 14 were girls, median age was 36(4-144) months and median follow-up period was 12.5 (ranged 2-106) months, and 10 were infants. All patients were given induction chemotherapy and the high-risk project of CCLG-ALL 2008. At the last time of follow-up, five patients gave up and were loss to follow-up. The 5 years OS and EFS were 52.2% and 47.8% respectively for the other 23 patients. The 5 years OS and EFS(28.6% and, 88.9%), (P=0.012), (28.6%, 77.8%), (P=0.048) rate of WBC≥50×10The 5 years OS is 52.2% and 5 years EFS is 47.8% for those ALL patients with MLL gene rearrangement. The WBC≥50×1028例MLL阳性急性淋巴细胞白血病患儿的治疗转归.分析MLL回顾性分析自2008年1月至2015年4月在中国医学科学院血液病医院儿童血液病中心就诊应用CCLG-2008-ALL方案治疗的28例年龄小于12岁MLL28例患者中男性14例，女性14例，中位年龄为36（4-144）个月，其中1岁以下患者共计10例。中位随访时间为12.5（2-106）个月。所有患儿均采用CCLG- 2008-ALL高危组治疗方案诱导及巩固化疗，直至末次随访日期（2019年6月1日），5例患者诱导治疗后早期放弃治疗，后期失访，剩余23例可分析的患者5年EFS和OS率分别为47.8%和52.2%。初诊时白细胞数≥50×10本研究中伴有MLL 阳性的急性淋巴细胞白血病患者5年OS率为52.2%，5年EFS率为47.8%。白细胞数≥50×10